Status:
RECRUITING
SloMo2: Implementation, Effectiveness, and Cost-effectiveness Study
Lead Sponsor:
King's College London
Collaborating Sponsors:
South London and Maudsley NHS Foundation Trust
Sussex Partnership NHS Foundation Trust
Conditions:
Schizophrenia Spectrum and Other Psychotic Disorders
Affective Psychoses
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Worries about harm from others (also known as paranoia) are common. Thinking fast or going on gut feelings is natural but can fuel these worries. For some, fast thinking and worries start to get in th...
Detailed Description
DESIGN AND AIMS The study is a repeated measures design, with clinical outcome assessments pre- and post-delivery of SloMoR2, and a 6-month follow-up for health economics data collection. The aim is t...
Eligibility Criteria
Inclusion
- Meet criteria for ICD-10 psychosis diagnoses (F20-29, F30-39)
- Seeking therapy for paranoia
- In contact with secondary care mental health services
- Capacity to provide informed consent to engage in therapy
Exclusion
- Acute risk of harm to self or others
- Unable to engage in therapy due to language barriers
- Primary diagnosis of alcohol/substance dependence, learning disability, or organic brain injury or illness implicated in psychosis
Key Trial Info
Start Date :
October 16 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2026
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT06568081
Start Date
October 16 2024
End Date
September 1 2026
Last Update
December 20 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
South London and Maudsley NHS Foundation Trust
London, United Kingdom